Tenaya Therapeutics (TNYA) Income from Continuing Operations (2020 - 2026)
Tenaya Therapeutics' quarterly Income from Continuing Operations came in at 19272000.0 in Q1 2026, up 28.26% year-on-year from 15025627.12 in Q1 2025, and up 4.48% quarter-over-quarter from 20175000.0 in Q4 2025.
Tenaya Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 19272000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 28.26% year-over-year to 19272000.0; the trailing twelve-month figure through Mar 2026 stood at 83005000.0 (up 21.52% YoY), and the FY2025 full-year result was 90597000.0, up 18.48% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19272000.0, up from 20175000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 19272000.0 in Q1 2026, with the low at 33516000.0 in Q4 2022.
- Average Income from Continuing Operations over 5 years is 27573352.94, with a median of 29143000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations tumbled 137.1% in 2022 and climbed 28.26% in 2026.
- Tracing TNYA's Income from Continuing Operations over 5 years: stood at 33516000.0 in 2022, then advanced by 10.68% to 29935000.0 in 2023, then increased by 20.37% to 23836000.0 in 2024, then grew by 15.36% to 20175000.0 in 2025, then increased by 4.48% to 19272000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19272000.0 (Q1 2026), 20175000.0 (Q4 2025), and 20275000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | -19.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.27 Mn |
| Dec 31, 2025 | -20.18 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -23.28 Mn |
| Mar 31, 2025 | -26.86 Mn |
| Dec 31, 2024 | -23.84 Mn |
| Sep 30, 2024 | -25.63 Mn |
| Jun 30, 2024 | -29.43 Mn |
| Mar 31, 2024 | -32.23 Mn |
| Dec 31, 2023 | -29.94 Mn |
| Sep 30, 2023 | -29.14 Mn |
| Jun 30, 2023 | -33.27 Mn |
| Mar 31, 2023 | -31.74 Mn |
| Dec 31, 2022 | -33.52 Mn |
| Sep 30, 2022 | -30.70 Mn |
| Jun 30, 2022 | -28.40 Mn |
| Mar 31, 2022 | -31.06 Mn |
| Dec 31, 2021 | -26.15 Mn |
| Sep 30, 2021 | -18.26 Mn |
| Jun 30, 2021 | -15.21 Mn |
| Mar 31, 2021 | -13.10 Mn |
| Dec 31, 2020 | -10.32 Mn |
| Sep 30, 2020 | -10.30 Mn |
| Jun 30, 2020 | -8.73 Mn |